Cancer Awareness Through Research And Education Association

Organization Overview

Cancer Awareness Through Research And Education Association, operating under the name CAREDESERT MOUNTAIN MEMBERS' CARE Desert Mountain Members' CARE, is located in Carefree, AZ. The organization was established in 2007. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. CAREDESERT MOUNTAIN MEMBERS' CARE Desert Mountain Members' CARE is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 06/2022, CAREDESERT MOUNTAIN MEMBERS' CARE Desert Mountain Members' CARE generated $969.1k in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 8.8% each year. All expenses for the organization totaled $906.0k during the year ending 06/2022. While expenses have increased by 7.7% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.

Since 2015, CAREDESERT MOUNTAIN MEMBERS' CARE Desert Mountain Members' CARE has awarded 18 individual grants totaling $5,245,840. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2022

Describe the Organization's Mission:

Part 3 - Line 1

CARE PROMOTES AWARENESS ABOUT CANCER TREATMENT AND PREVENTION THROUGH EDUCATIONALFORUMS AND SEMINARS AND RAISES MONEY TO PROVIDE SEED-FUNDING TO FUND INNOVATIVE NEW CANCER RESEARCH PROJECTS AND CLINICAL TRIALS IN THE PHOENIX AREA.

Describe the Organization's Program Activity:

Part 3 - Line 4a

MAYO CLINIC IN AZ - FUNDING TWO MAYO CLINIC PROJECTS: 1) PREDICTING METASTATIC POTENTIAL CUTANEOUS SQUAMOUS CELL CARCINOMA, AND 2) TARGETING METASTATIC PROSTATE CANCER WITH NOVEL FN14PREDICTING METATASIC POTENTIAL CUTANEOUS SQUAMOUS CELL CARCINOMA USING GENE EXPRESSION PROFILING:CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) AFFECTS MORE THAN ONE MILLION INDIVIDUALS ANNUALLY IN THE UNITED STATES. ITS INCIDENCE IS RISING DUE TO ULTRAVIOLET EXPOSURE AND AN INCREASE IN THE POPULATION OF ELDERLY AND IMMUNOSUPPRESSED INDIVIDUALS. MOST CSCC IS CURABLE BY SURGERY, BUT METASTASIS OCCURS IN UP TO 5% OF PATIENTS. METASTATIC CSCC CARRIES A POOR FIVE-YEAR SURVIVAL (25-35%) AND ACCOUNTS FOR NEARLY 8,800 DEATHS ANNUALLY, COMPARABLE TO THE MORTALITY RATE OF MALIGNANT MELANOMA.THERE IS A GREAT NEED FOR MORE ACCURATE IDENTIFICATION OF TUMORS WITH METASTATIC POTENTIAL TO TRULY CHARACTERIZE CSCC PATIENTS THAT ARE AT HIGH RISK. MAYO CLINICS RESEARCH TEAM HAS DEVELOPED A METHOD BASED ON GENE EXPRESSION PROFILING (GEP) THAT CAN STRATIFY INTERMEDIATE TO HIGH-RISK CSCC FOR OVERALL SURVIVAL BY 20-FOLD AND CAN PROPERLY STRATIFY 95% OF INTERMEDIATE TO HIGH-RISK TUMORS AS NON-METASTATIC AND 70% OF INTERMEDIATE TO HIGH-RISK TUMORS AS METASTATIC. VALIDATION OF THIS PANEL WOULD PERMIT DESIGN OF NOT ONLY A NEW TEST, BUT AN ENTIRE NEW WAY OF ASSESSING THE RISK IN ONE OF THE MOST COMMON HUMAN CANCERS, SCC.TARGETING METASTATIC PROSTATE CANCER WITH NOVEL FN14 INHIBITORY COMPOUND:PROSTATE CANCER (PCA) IS THE SECOND LEADING CAUSE OF CANCER RELATED DEATH IN AMERICAN MEN. LIKE NORMAL PROSTATE TISSUE, WHICH REQUIRES ANDROGEN HORMONES PRODUCED BY THE BODY TO FUNCTION, SO DO PROSTATE CANCER CELLS. THUS, TREATMENT FOR PCA FREQUENTLY INVOLVES EITHER REDUCING THE SUPPLY OF ANDROGENS BY BLOCKING ANDROGEN SYNTHESIS IN THE BODY OR DISRUPTING THE STIMULATION OF CANCER CELLS THROUGH BLOCKADE OF ANDROGEN RECEPTOR SIGNALS IN CANCER CELLS. THIS APPROACH IS KNOWN AS ANDROGEN DEPRIVATION THERAPY (ADT). ALTHOUGH INITIAL RESPONSE RATES ARE PROMISING, ALL MEN EVENTUALLY PROGRESS ON ADT AND DEVELOP A RESISTANT VERSION OF PROSTATE CANCER, WHICH UNDERGOES METASTATIC SPREAD. AT THIS METASTATIC STAGE, SPECIFICALLY WHEN METASTASIZED TO THE BONE, PCA IS INCURABLE, AND AN INCREASING NUMBER OF MEN ARE DEVELOPING A HIGHLY LETHAL VARIANT OF PCA KNOWN AS AGGRESSIVE VARIANT PROSTATE CANCER (AVPC). ANDROGEN RECEPTOR SIGNALING IS LOST IN AVPC RENDERING THE EXISTING HORMONE TARGETING TREATMENTS INEFFECTIVE. TO DATE, VERY FEW THERAPIES EXIST FOR AVPC AND ONLY OFFER MINIMAL SURVIVAL BENEFITS IN THIS SETTING. THUS, THE IDENTIFICATION AND ASSESSMENT OF DRUG TARGETING VAPC ARE NEEDED TO EFFECTIVELY TREAT AND CONTROL METASTASIS.


HONORHEALTH RESEARCH INSTITUTE - FUNDING TWO HHRI PROJECTS: 1) UVEAL MELANOMA STUDY, AND 2) TENOSYNOVIAL GIANT CELL TUMOR STUDYUVEAL MELANOMA:UVEAL MELANOMA (UM) IS A RARE SUBTYPE THAT ARISES TYPICALLY IN THE CHOROIDAL BODY OF THE EYE. UNLIKE CUTANEOUS (SKIN) MELANOMA, UM HAS BEEN RESISTANT TO CURRENT IMMUNOTHERAPY AND AT THE PRESENT TIME, THERE IS NO FDA APPROVED TREATMENT FOR THIS DISEASE MAKING IT BOTH A RARE AND REFRACTORY DISEASE. HHRIS GOAL IS TO IDENTIFY NOVEL BIOMARKERS FOR DISEASE MONITORING AND DIAGNOSIS WITH THE EXPECTATION THAT SUCH BIOMARKERS CAN BE USED TO IDENTIFY PATIENTS AT HIGHEST RISK FOR RECURRENCE AND UTILIZE THESE BIOMARKERS AS A SURROGATE ENDPOINT IN THE ADJUVANT SETTING.TENOSYNOVIAL GIANT CELL TUMOR: TENOSYNOVIAL GIANT CELL TUMOR (TGCT) IS A RARE SARCOMATOUS PROLIFERATION OF THE SYNOVIUM LINING THE JOINTS. THIS DISORDER TYPICALLY OCCURS IN YOUNG MEN AND WOMEN AND MOST OFTEN IMPACT THE LARGE JOINTS, PARTICULARLY THE KNEES.BY THE TIME PATIENTS PRESENT FOR DIAGNOSIS, THE TGCT PROLIFERATION IF MOST OFTEN NOT COMPLETELY RESECTABLE AND SURGERY HAS LIMITED VALUE. MRI SCANS HAVE CLASSICAL FEATURES FOR THIS DIAGNOSIS BUT SUFFER FROM INACCURACY AND THE FACT THAT A TISSUE DIAGNOSIS IS NEEDED TO MOVE FORWARD WITH SYSTEMIC THERAPY. TREATMENT FOR TGCT INCLUDES THE ORALLY ADMINISTERED TARGETED DRUG PEXIDARTINIB WHICH CAN BE ASSOCIATED WITH THE DEVELOPMENT OF LIVER FAILURE MAKING ITS USE SOMEWHAT COMPLEX. THE LACK OF A SIMPLE DIAGNOSTIC TEST, AS OPPOSED TO HAVING TO PROCEED WITH SURGERY AND BIOPSY, PLACES PATIENTS AT GREATER RISK FOR COMPLICATIONS. WE HAVE IDENTIFIED THIS AS A POTENTIALLY GAME-CHANGING OPPORTUNITY SINCE MOST OF THESE PATIENTS PRESENT NOT ONLY WITH THE SYNOVIAL PROLIFERATION BUT ALSO WITH A DETECTABLE JOINT EFFUSION (FLUID) THAT CAN BE ASPIRATED. HHRI IS PROPOSING TO SUBJECT NEW DIAGNOSED AND UNTREATED PATIENTS TO A JOINT EFFUSION ASPIRATION AS WELL AS THE NECESSARY SURGICAL BIOPSY (IF NOT ALREADY PERFORMED) TO DEVELOP AN EFFUSION-DRIVEN BIOMARKER ANALYSIS ALLOWING AN ALTERNATE MECHANISM FOR SECURING THE DIAGNOSIS OF TGCT


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Board, Officers & Key Employees

Name (title)Compensation
Jill Porcellato
Chairman
$0
J Derek Hill
Treasurer
$0
Suzanne Paetzer
Vice Chair/secr
$0
Syliva Owens
Director
$0
Wayne Malloux
Director
$0
Michael Blaszyk
Director
$0

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$359,830
Related organizations$0
Government grants $0
All other contributions, gifts, grants, and similar amounts not included above$725,430
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$1,085,260
Total Program Service Revenue$0
Investment income $28
Tax Exempt Bond Proceeds $0
Royalties $0
Net Rental Income $0
Net Gain/Loss on Asset Sales -$183
Net Income from Fundraising Events -$165,665
Net Income from Gaming Activities $49,695
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $969,135

Grants Awarded

Over the last fiscal year, Cancer Awareness Through Research And Education Association has awarded $880,000 in support to 2 organizations.

Grant RecipientAmount

HONORHEALTH RESEARCH INST

Org PageRecipient Profile

Scottsdale, AZ

PURPOSE: SEED FUNDING-ASSISTANCE

$440,000

Rochester, MN

PURPOSE: SEED FUNDING-ASSISTANCE

$440,000
View Grant Profile

Grants Recieved

Over the last fiscal year, we have identified 2 grants that Cancer Awareness Through Research And Education Association has recieved totaling $40,000.

Awarding OrganizationAmount
Donald & Kimberlee Slager Foundation

Wilmington, DE

PURPOSE: GENERAL & UNRESTRICTED

$25,000
Hunter Pryor Family Foundation

Wilmington, DE

PURPOSE: GENERAL & UNRESTRICTED

$15,000
View Grant Recipient Profile

Create an account to unlock the data you need.

or